![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 49, 46852-46857, December 6, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, July 31, 2002, and in revised form, September 5, 2002
The serine protease tissue-type plasminogen
activator (t-PA) initiates the fibrinolytic protease cascade and plays
a significant role in motor learning, memory, and neuronal cell death
induced by excitotoxin and ischemia. In the fibrinolytic system, the
serpin PAI-1 negatively regulates the enzymatic activity of both
single-chain and two-chain t-PA (sct-PA and tct-PA). In the central
nervous system, neuroserpin (NSP) is a serpin thought to regulate t-PA enzymatic activity. We report that although both sct-PA and tct-PA rapidly form acyl-enzyme complexes with NSP in vitro, the
interactions are short-lived, rapidly progressing to complete cleavage
of NSP and regeneration of fully active enzyme. All NSP molecules
appear to transit through the detectable acyl-enzyme intermediate and progress to completion of cleavage; no subpopulation that
functions as a pure substrate was detected. Likewise, all molecules
were reactive, with no evidence of a latent subpopulation. The
interactions between NSP and t-PA were distinct from those between
plasmin and NSP, wherein the same peptide bond was cleaved but there
was no evidence of a detectable plasmin-NSP acyl-enzyme complex.
The interactions between t-PA and NSP contrast with the
formation of long-lived, physiologically irreversible acyl-enzyme
complexes between t-PA and PAI-1, suggesting that the physiologic
effect of t-PA-NSP interactions may be more complex than previously thought.
Tissue-type plasminogen activator
(t-PA)1 is one of two
mammalian serine proteases that activate plasminogen to plasmin. Unlike the zymogen form of most serine proteases, the single-chain form of
t-PA (sct-PA) retains roughly 10-25% of the enzymatic activity of the
mature two-chain form (tct-PA) (1-3). Because both sct-PA and tct-PA
are active enzymes, inhibition of t-PA activity, rather than
maintenance of the protease in zymogen form, is necessary to prevent
undesired proteolysis. In plasma, the physiologic or cognate inhibitor
of t-PA appears to be the serine protease inhibitor (serpin)
plasminogen activator inhibitor type-1 (PAI-1) (4).
In addition to its role in maintaining vascular hemostasis, t-PA is a
key extravascular protease in the central and peripheral nervous
systems. t-PA can be detected on the axonal growth cone of developing
neuroblasts (5) and is involved with motor learning and memory (6).
Studies in t-PA null mice have shown that t-PA enzymatic activity
mediates neuronal cell death associated with both seizure kindling and
ischemia and is involved with myelinated nerve regeneration following
nerve crush injury (7-9).
To date, the mechanism by which t-PA activity in the nervous system is
regulated is unknown, although several studies have suggested that the
recently described serpin, neuroserpin (NSP), may serve this function
(10, 11). NSP is an ~45-kDa glycosylated serpin that is expressed
almost exclusively in the nervous system throughout embryologic
development and adulthood (12). NSP inhibits the enzymatic activity of
t-PA in vitro (10), and pharmacologic administration of NSP
to rats that have undergone middle cerebral artery occlusion
decreases the volume of the ischemic penumbral area concomitant with
inhibition of t-PA enzymatic activity (13). Also, transgenic mice that
overexpress NSP show a decreased volume of neuronal cell death
following middle cerebral artery occlusion compared with their wild
type counterparts (14). It is presumed that NSP inhibits t-PA in a
manner analogous to PAI-1 to mediate these effects.
Serpins inhibit the enzymatic activity of their cognate serine
proteases via initial formation of a Michaelis complex in which the
enzyme is reversibly bound and inhibited by the serpin (15). The
protease initiates cleavage of the scissile peptide bond between the P1
and P1' residues of the reactive center loop, which leads to the
formation of an acyl-enzyme intermediate, with the active site serine
covalently bound to the P1 residue (16, 17). However, presumably before
this intermediate can be hydrolyzed to yield cleaved serpin and active
protease (i.e. completion of the cleavage reaction), the
protease, bound to the P1 residue of the serpin, is translocated to the
opposite pole of the serpin (18). The tertiary structure of the
translocated protease active site is sufficiently disrupted to prevent
hydrolysis of the acyl-enzyme complex (19), making the rate of
deacylation extremely slow (i.e. weeks). The complexes
display new molecular determinants that allow for cellular
internalization and degradation in a matter of minutes (20). Therefore,
protease-serpin acyl-enzyme complex formation can usually be viewed as
biologically irreversible.
The work presented here demonstrates that the interaction of NSP with
its putative cognate protease, t-PA, differs from the currently held
paradigm in that the acyl-enzyme intermediates between t-PA and NSP are
much less stable than other cognate protease-serpin complexes. Indeed,
t-PA seems to handle NSP more like a substrate than a suicide
inhibitor, with the acyl-enzyme complex being a detectable
intermediate. These findings may provide insights into the physiologic
interaction between NSP and t-PA, which may differ from certain
functions inferred from studies with pharmacological concentrations of
NSP in animal models.
Proteins and Reagents--
Sct-PA (greater than 95%
single-chain t-PA) isolated from Bowes melanoma cells was purchased
from Biopool and from Calbiochem. Tct-PA was generated by
treating sct-PA with plasmin linked to Sepharose beads
(plasmin-Sepharose) at 37 °C for times determined in preliminary
experiments, to yield complete cleavage of sct-PA by that batch of
plasmin-Sepharose as determined by silver staining of
SDS-polyacrylamide gels run under reducing conditions. Human scu-PA was
a generous gift from Dr. Jack Henkin of Abbott Laboratories. Human
tcu-PA (Winkinase) was obtained from Dr. Gene Murano, Monsanto, St.
Louis, MO.
The cDNA for human NSP was obtained from Human Genome Sciences,
Rockville, MD. Recombinant human NSP was expressed and purified from
a baculovirus-based system. PAI-1 (14-1b mutant) was expressed and purified from Escherichia coli as described previously
(10, 21) and was ~50% active as measured by stable inhibition of tct-PA. Polyclonal antibodies against NSP were generated in rabbits (10). Plasminogen was radioiodinated as described previously (22, 23).
Plasmin, aprotinin, and spectrozyme t-PA were purchased from American
Diagnostica, Greenwich, CT. Bovine serum albumin, obtained from Sigma,
was treated with 100 µM diisopropyl
fluorophosphate to inhibit potentially contaminating serine
proteases, followed by exhaustive dialysis. Horseradish
peroxidase-conjugated goat anti-rabbit IgG secondary antibody was
purchased from Pierce. Kodak 1-D Image software was used to digitize
and quantify bands on autoradiograms and Western blots. All
electrophoresis and protein transfers were carried out in the Bio-Rad
Mini-protein 3 system. Electrophoresis reagents and precast 8-16%
gradient SDS-polyacrylamide gels were purchased from Bio-Rad.
SDS-Polyacrylamide Electrophoresis and Western
Blotting--
10% polyacrylamide gels with a 3% stacking gel or
precast 8-16% gels with a 4% stacking gel were used as noted in each
figure legend. The gradient gel system was selected for optimal
separation of 40- and 45-kDa NSP species but does not allow for optimal
detection of NSP·t-PA acyl-enzyme complexes. A 10% separating
gel was used for experiments in which optimal detection of NSP·t-PA
acyl-enzyme complexes was necessary. NSP was detected immunologically
after electrophoresis by electroblotting proteins from the gel to
polyvinylidene difluoride membrane for 1 h at 100 V (24, 25).
Membranes were then blocked with Tris-buffered saline, 0.01 M Tris, 0.15 M NaCl, pH 7.2, containing 0.05%
Tween and 0.25% gelatin and then blotted with a 1:5000 dilution of
rabbit antibody against NSP (10) (demonstrated in preliminary
experiments to be specific for NSP and to detect intact, cleaved, and
complexed NSP) in the blocking buffer followed by blotting with a
1:5000 dilution of horseradish peroxidase-conjugated goat antibody
against rabbit IgG in the blocking buffer. Membranes were then rinsed
several times in Tris-buffered saline with 0.05% Tween and
subsequently treated with Pierce West Super Pico Enhanced Chemiluminescence Reagent, then exposed to film.
Inhibition of t-PA by NSP--
Assays to monitor the cleavage of
125I-plasminogen were performed as described previously
(26). Plasminogen activation was quantified by measuring the plasmin
light chain band (26). The percentage of t-PA activity remaining for
each concentration of inhibitor was determined by the formula,
Assays of t-PA activity using chromogenic substrates were
performed in Tris-imidazole buffer, ionic strength 0.3, pH 8.4, at room
temperature. t-PA and serpin (145-150 nM each) were
incubated for the indicated times followed by the addition of
spectrozyme t-PA at a final concentration of 500 µM. The
kinetics program on a Beckman DU-640 spectrophotometer was used at 1 reading/s at 440 nM for 1 min. Measurements were normalized
to exclude substrate autohydrolysis (measured in parallel reactions
lacking t-PA). The percentage of active t-PA was determined by the
formula,
Formation and Deacylation of Protease-NSP Acyl-Enzyme
Complexes--
NSP and the specified protease were incubated at the
indicated concentrations, temperatures, and times in buffer
containing 0.1 M NaH2PO4, 0.1%
Triton X-100, and 100 µg/ml bovine serum albumin, pH 7.2. Reactions
were stopped by the addition of SDS sample buffer followed by SDS-PAGE
and Western blot analysis as described. Detection of high
Mr bands as would be expected for a complex
between that protease and NSP was taken as evidence of acyl-enzyme
formation (10, 16, 19). Detection of an ~40-kDa band by anti-NSP
antibody was consistent with complete cleavage of NSP and hence of deacylation.
Determination of Cleavage Site within NSP--
NSP (12 µg) and
tct-PA (2.8 µg) or plasmin (2.8 µg) were combined in a 10-µl
total volume for 40 min at 37 °C. Reactions were quenched by the
addition of phenylmethylsulfonyl fluoride. Reaction products were
separated by electrophoresis on a 3% stacking, 10% spacing, and 20%
separating SDS-polyacrylamide gel followed by transfer to a
polyvinylidene difluoride membrane (27). Coomassie Blue-stained peptide
bands were then excised and subjected to Edman degradation analysis
using a Procise 494HT (Applied Biosystems, Foster City, CA)
peptide sequence apparatus.
NSP Inhibition of t-PA Proteolytic Activity--
In agreement with
previous findings, NSP inhibited t-PA cleavage of the chromogenic
substrate spectrozyme t-PA (Table I) (10). However, NSP was a poor inhibitor of t-PA cleavage of 125I-plasminogen, even at a 1000-fold molar excess of
serpin over either sct-PA or tct-PA (Fig.
1, Table I). This was not because of some
unique aspect of the 125I-plasminogen cleavage assays, as
PAI-1 efficiently inhibited both forms of t-PA in parallel
125I-plasminogen cleavage assays, with the previously
described differential susceptibility of the single-chain and two-chain
forms of t-PA to PAI-1 inhibition (4) (Fig. 1).
The assays monitoring cleavage of chromogenic substrate and
125I-plasminogen differ not only in the substrate being
cleaved but also in the time frame of the reactions. The
125I-plasminogen cleavage reaction requires hours for
evidence of t-PA activity to be detectable, whereas only minutes are
needed for the chromogenic substrate based assay. The difference in
t-PA inhibition by NSP seen in these two assays suggests that the
inhibition of t-PA by NSP may be a function of time. To investigate the
time-dependence of t-PA-NSP interaction, each form of t-PA was combined
with NSP at 37 °C, and the fate of NSP was followed as the reactions
progressed (Fig. 2). At early time
points, NSP and either sct-PA or tct-PA yielded a product
characteristic of acyl-enzyme complex formation (high
Mr band). However, at subsequent time points the
intensity of the acyl-enzyme band decreased, and coincident with this
an ~40-kDa band was observed, suggesting that NSP in complex with t-PA was undergoing completion of the cleavage reaction. Both the
appearance of acyl-enzyme complexes and their presumed hydrolysis occurred much more rapidly with two-chain than with single-chain t-PA,
consistent with the greater catalytic efficiency of tct-PA in solution.
These results suggest that, similar to PAI-1, NSP inhibits t-PA via
acyl-enzyme complex formation (inhibition detected in assay over short
time). However, in contrast to t-PA·PAI-1, t-PA·NSP acyl-enzyme
complexes are relatively unstable, undergoing deacylation in a matter
of minutes (assays requiring longer time courses do not detect this
transient inhibition). These data suggest that the acyl-enzyme complex
between either form of t-PA and NSP might be characterized as a
"stutter-step," e.g. a detectable intermediate in
the process of peptide bond cleavage by the protease. An interesting
structural implication is that the deformation of the active site that
accompanies rearrangement of protease-serpin pairs may not be as
extensive for t-PA·NSP as for other protease-serpin pairs.
To determine whether such transient acyl-enzyme complexes are a
property of NSP interactions with any protease, reactions between
plasmin and NSP and between u-PA and NSP were examined. Fig.
3 demonstrates that plasmin efficiently
cleaves NSP with no detection of plasmin-NSP complexes. Fig.
4 demonstrates that scu-PA yields neither
detectable complex formation with nor cleavage of NSP; whereas tcu-PA
cleaves NSP with a trace of transient acyl-enzyme complexes detected on
overexposed autoradiograms (not shown). Hence, the existence of a
quantitatively significant acyl-enzyme intermediate seems to be a
unique property of the NSP-t-PA interaction.
Examination of the amino acid sequence of the reactive center loop of
NSP suggests three potential sites for cleavage by trypsin-like proteases Arg362, Arg384, and
Arg393. Thus, it was conceivable that different proteases
hydrolyze different peptide bonds in NSP, with the one targeted by t-PA yielding a loop of the appropriate length to allow for translocation of
the protease in a transiently stable arrangement and the site targeted
by plasmin yielding a loop that was too long for stabilization of the
intermediate (28). However, for both enzymes, the target P1-P1' bond
was determined to be Arg362-Met363 by
N-terminal sequencing of the C-terminal cleavage peptide (Table II). Hence, plasmin and t-PA both cleave
the same P1-P1' bond, but the outcome of the
interaction of t-PA with NSP is a detectable albeit transient
acyl-enzyme, whereas plasmin treats NSP solely as a substrate without
evidence of the covalent serpin-protease complex. It is not clear
whether this reflects a more rapid rate of deacylation by plasmin such
that there is insufficient time for translocation (18) or whether the
different surface topographies of the proteases result in a molecular
alignment between NSP and plasmin that is suboptimal for the active
site deformation required for a detectable acyl-enzyme complex.
To ensure that the observed transient stability of t-PA·NSP
acyl-enzyme complexes was a true reflection of the protein properties and not a function of an SDS-PAGE-based assay (29, 30), a chromogenic
substrate-based assay of t-PA enzymatic activity was used. Equimolar
amounts of NSP and t-PA were incubated for increasing times, t-PA
enzymatic activity was monitored via cleavage of chromogenic substrate
(Fig. 5, A and B),
and aliquots of the same reactions were analyzed by SDS-PAGE and
Western blotting to determine the fate of the NSP (Fig. 5, C
and D). Fig. 5 demonstrates that with increasing time, the
enzymatic activity of t-PA that had been inhibited by NSP was recovered
(Fig. 5, A and B, enzymatic activity), concomitant with the generation of cleaved NSP (Fig. 5, C
and D; the appearance of the 40-kDa cleavage product
demonstrating deacylation had occurred). Control experiments with t-PA
inhibition by PAI-1 (Fig. 5, A and B) yielded no
recovery of enzymatic activity of either form of t-PA subsequent to
their interaction with PAI-1. Hence, the transient stability of
t-PA·NSP acyl-enzyme complexes is a property of the reactants and is
not a function of the assay. In addition, these data demonstrate that
functional t-PA is recovered with deacylation of t-PA·NSP
complexes.
Figs. 2 and 5 also demonstrate that NSP cleavage by either form of t-PA
proceeds via the transient acyl-enzyme intermediate, with little
evidence for a NSP population that acts as a pure t-PA substrate.
Slowing the reaction by carrying it out at 4 °C revealed that
cleaved NSP was preceded by the appearance of acyl-enzyme complexes
(Fig. 6). Hence, even under conditions
that favor substrate behavior by serpins (lowering the reaction
temperature fosters the substrate behavior of serpins due to slowing of
protease translocation, a temperature-sensitive process, with little
influence on deacylation) (31), all NSP proceeds to cleavage via the
acyl-enzyme intermediate. In addition, all of the NSP is eventually
cleaved, without evidence of a latent form of the serpin (Fig. 2 for
tct-PA, not shown for sct-PA). Therefore, NSP appears to act as a
single population of molecules that is cleaved by t-PA via transition
through a detectable acyl-enzyme intermediate.
The data presented thus far suggest that the interactions between NSP
and t-PA are more similar to cleavage of a substrate with a protracted
intermediate than the biologically irreversible inhibition usually
associated with serpins. If this is the case, inclusion of NSP in an
assay that measures t-PA enzymatic activity over a time period that
allows deacylation to occur should yield a pattern more similar to that
of a substrate than to the pattern seen with PAI-1. To test this
hypothesis, the inhibition profiles of sct-PA- and tct-PA-mediated
125I-plasminogen cleavage by PAI-1, NSP, and a physiologic
substrate, unlabeled plasminogen, were compared. The NSP inhibition
profiles of both forms of t-PA are very similar to the profiles of
inhibition by a competitive substrate, unlabeled plasminogen, and
differ from the inhibition profiles of PAI-1 (Fig.
7). This difference is unlikely to be due
solely to differences in affinities of t-PA for PAI-1 versus
NSP, as the time to onset and extent of maximal protease inhibition by
PAI-1 and NSP appeared to be similar in the chromogenic substrate-based
assays detailed in Fig. 5.
It seems that NSP is neither a pure inhibitor nor a pure substrate of
t-PA, as the rate of NSP-t-PA acyl-enzyme complex deacylation in
vitro is rapid enough to make inhibition transient, at best, but
slow enough to constitute a significant kinetic stutter step in the
substrate behavior of NSP and therefore to interrupt proteolysis of an
alternative substrate by t-PA. Such an interpretation is consistent
with the protective effects seen with transgene-driven overexpression
of NSP or with the administration of pharmacological concentrations of
NSP into the central nervous system of mice with middle cerebral artery
occlusion (13, 16).
Another aspect to be considered is the effect of plasmin on
NSP-sensitive processes. If t-PA effect in the central nervous system is plasminogen-dependent, as much data suggest (32), the rapid and efficient cleavage of NSP by plasmin will have to be
considered and balanced against the blunting of plasmin generation by
NSP. Likewise, if NSP is ultimately cleaved by both t-PA and plasmin, a
potential but heretofore unknown function for cleaved NSP may be part
of the process.
According to its predicted structure, NSP bears a series of negatively
charged residues in an alignment similar to the positively charged
residues on the face of the D-helix in certain serpins that bind
heparin with resultant augmented inhibitory activity (33). As such,
there is the possibility that a positively charged cofactor binds NSP
and augments or stabilizes its inhibitory activity. Such a cofactor was
sought by combining NSP with homogenates of mouse hippocampus to allow
for interaction between NSP and a potential cofactor, followed by the
addition of t-PA. There was no evidence of improved efficiency of t-PA
inhibition or of stabilization of t-PA·NSP complexes (data not shown).
The data presented above raise intriguing questions about
the nature of the physiologic interaction between t-PA and NSP. In
processes involving other protease-serpin pairs, the acyl-enzyme complex presents molecular determinants not present on the individual reactants that allow cellular internalization of the complex, classically via the LDL receptor-related protein molecule (17). The time required for complex internalization in in vitro
experiments (34) suggests that this process may not be rapid enough to
clear t-PA·NSP complexes before deacylation at 37 °C. Hence, it
will be of interest to determine whether t-PA·NSP acyl-enzyme
complexes have a different fate than do other protease-serpin pairs.
Alternatively, given that sct-PA·NSP complexes are longer lived than
tct-PA·NSP complexes, NSP may serve to selectively inactivate or
mediate clearance of sct-PA. At present, however, these remain
speculations to be tested experimentally.
Given that stable acyl-enzyme complexes are characteristic of cognate
protease-serpin pairs, with relatively unstable complexes being
observed in some noncognate pairs (35), it seems reasonable to examine
whether NSP is indeed a physiologic inhibitor of t-PA. Relating the
data in statement (i) that families with a point mutation of
NSP, resulting in in situ polymerization of NSP and presumably a decrease in soluble NSP, manifest their first clinical signs of disease as spontaneous seizures (36), and the data in
statement (ii) rodent models demonstrate t-PA-dependent
propagation of seizures that is blocked by NSP (37), it seems likely
that a t-PA-NSP interaction takes place in vivo as a part of
seizure-prevention processes. It will therefore be important to
reconcile the observed biochemical characteristics of NSP with
observations on its in vivo actions.
We thank Henriette Remmer and Karen
Avenatti from the Protein Sciences Facility, University of
Illinois for assistance in N-terminal peptide sequence analysis. We
would also like to thank Richard Guerra for work on the interactions
between urokinase and NSP and Debora McCall for help and
expertise in preparation of this manuscript.
*
This work was supported by National Institutes of Health
Grants HL43506 (to B. S. S.), HL55374, and HL55747 (to D. A. L.). Part of this work was presented in abstract form at the International Society for Thrombosis and Hemostasis Meeting, July 2001, and part was
presented at the Workshop on the Molecular and Cell Biology of
Plasminogen Activation, September 2001.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence should be addressed: 190 Medical Sciences
Bldg., MC-714, 506 S. Mathews, Urbana, IL 61801. Tel.: 217-333-5465; Fax: 217-333-8868; E-mail: schwart2@uiuc.edu.
Published, JBC Papers in Press, September 11, 2002, DOI 10.1074/jbc.M207740200
The abbreviations used are:
t-PA, tissue-type
plasminogen activator;
sct-PA, single-chain t-PA;
tct-PA, two-chain
t-PA;
scu-PA, single chain urokinase plasminogen activator;
tcu-PA, two chain urokinase plasminogen activator;
NSP, neuroserpin;
PAI-1, plasminogen activator inhibitor type-1.
Acyl-Enzyme Complexes between Tissue-type Plasminogen Activator
and Neuroserpin are Short-lived in Vitro*
§,
**
Department of Biomolecular Chemistry and the
§ Medical Scientist Training Program, University of
Wisconsin, Madison, Wisconsin 53706, the ¶ Department of Vascular
Biology, American Red Cross Holland Laboratory, Rockville, Maryland
20855, and the
Departments of Biochemistry and Medicine,
University of Illinois, Urbana, Illinois 61801
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES
(Eq. 1)
Inhibition profiles were graphed using Prism 3 software.
(Eq. 2)
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES
t-PA inhibition by neuroserpin: variation according to assay

View larger version (63K):
[in a new window]
Fig. 1.
NSP is a less efficient inhibitor of sct-PA
or tct-PA than is PAI-1. 1.7 nM sct-PA (A)
and tct-PA (B) were incubated at 37 °C with the indicated
concentration of NSP (lanes 3-8) or PAI-1
(lanes 9-13) and 42 nM
125I-plasminogen for 24 h. The reactions were analyzed
by SDS-PAGE and autoradiography, with the light chain of
125I-plasmin (125IPN LC)
being an accurate measure of 125I-plasminogen
(125I-PG) cleavage as outlined under
"Materials and Methods." Lane 1 contains
125I-plasminogen (42 nM) incubated alone for
24 h at 37 °C, and lane 2 contains
125I-plasminogen incubated with t-PA in the absence of
inhibitor for 24 h.

View larger version (76K):
[in a new window]
Fig. 2.
t-PA·NSP acyl-enzyme complexes are
transient. 14 nM NSP was incubated alone at 37 °C
for 640 min (first lane on left) or with 14 nM sct-PA (A) or 14 nM tct-PA
(B) for the indicated times at 37 °C. In A,
reactions were quenched by the addition of nonreducing SDS sample
buffer, and in B, reactions were quenched by the addition of
reducing SDS sample buffer. Analysis was performed by SDS-PAGE followed
by immunoblotting with a polyclonal antibody directed against NSP as
described under "Materials and Methods."

View larger version (50K):
[in a new window]
Fig. 3.
Plasmin does not form acyl-enzyme complexes
with NSP. NSP (14 nM) alone (first lane in
each gel) or with plasmin (14 nM) was incubated for the
indicated times (lanes 2-9) at 37 °C (A) or
4 °C (B). Reactions were analyzed by SDS-PAGE and
immunoblotting as described under "Materials and Methods."

View larger version (63K):
[in a new window]
Fig. 4.
u-PA does not form acyl-enzyme complexes with
NSP. NSP (14 nM) alone (first lane of each
gel) or with scu-PA (14 nM; A) or tcu-PA (14 nM; B) was incubated for the times indicated at
37 °C. In B, second lane, 14 nM
tct-PA and 14 nM NSP were incubated for the indicated time
at 37 °C for a comparison of the extent of NSP cleaved by tct-PA and
by tcu-PA within the same time frame and under the same conditions.
Reactions were analyzed by SDS-PAGE and immunoblotting as described
under "Materials and Methods."
Determination of the proteolytic cleavage site in neuroserpin

View larger version (28K):
[in a new window]
Fig. 5.
t-PA enzymatic activity is recovered with
deacylation of NSP·t-PA acyl-enzyme complexes. Sct-PA
(A) or tct-PA (B) and NSP or PAI-1 (all reactants
were at 144 nM) were incubated at room temperature for the
times noted. An aliquot of each reaction was added to the chromagenic
substrate Spec-t-PA (500 µM), and the % active t-PA was
determined as described under "Materials and Methods." The fate of
the NSP in reactions A and B was determined by subjecting an aliquot of
each reaction to electrophoresis on an 8-16% gradient gel followed by
detection of NSP antigen as described under "Materials and Methods"
(C and D, respectively). Note that the 8-16%
gradient gel system was used expressly to detect the 40-kDa cleaved NSP
species as evidence of acyl-enzyme deacylaction.

View larger version (68K):
[in a new window]
Fig. 6.
NSP cleavage proceeds via the detectable
acyl-enzyme intermediate without evidence for a population of NSP
molecules that behave as a pure substrate. 14 nM NSP
was incubated with 14 nM sct-PA (A) or with 14 nM tct-PA (B) for the indicated times at 4 °C
to slow the reaction. Samples were quenched by the addition of
nonreducing SDS sample buffer. Reactions were analyzed by
SDS-PAGE and immunoblotting as described under "Materials and
Methods."

View larger version (19K):
[in a new window]
Fig. 7.
NSP interacts with t-PA with a profile more
consistent with a competitive substrate than an irreversible
serpin. Sct-PA and tct-PA (1.7 nM) were incubated with
42 nM 125I-plasminogen at 37 °C in the
presence of the indicated concentrations of either NSP, PAI-1, or
unlabeled plasminogen. The reactions were analyzed by SDS-PAGE under
reducing conditions followed by autoradiography. The percentage
inhibition of t-PA was determined by comparing the intensity of the
125I-plasmin light chain band to the band obtained in the
reaction lacking any inhibitor as described under "Materials and
Methods."
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES
1.
Boose, J. A.,
Kuismanen, E.,
Gerard, R.,
Sambrook, J.,
and Gething, M. J.
(1987)
Biochemistry
28,
635-643
2.
Ranby, M.,
Bergsdorf, N.,
and Nilsson, T.
(1982)
Thromb. Res.
27 (suppl.),
175-183[CrossRef][Medline]
[Order article via Infotrieve]
3.
Tachias, K.,
and Madison, E. L.
(1997)
J. Biol. Chem.
272,
28-31 4.
Kruithof, E. K.,
Tran-Thang, C.,
Ransign, A.,
and Bachmann, F.
(1984)
Blood
64,
907-913 5.
Pittman, R. N.,
Ivins, J. K.,
and Buettner, H. M.
(1989)
J. Neurosci.
9,
4269-4289[Abstract]
6.
Calabresi, P.,
Napolitano, M.,
Centonze, D.,
Marfia, G. A.,
Gubellini, P.,
Teule, M. A.,
Berretta, N.,
Bernardi, G.,
Frati, L.,
Tolu, M.,
and Gulino, A.
(2000)
Eur. J. Neurosci.
12,
1002-1012[CrossRef][Medline]
[Order article via Infotrieve]
7.
Tsirka, S. E.,
Gualandris, A.,
Amaral, D. G.,
and Strickland, S.
(1995)
Nature
377,
340-344[CrossRef][Medline]
[Order article via Infotrieve]
8.
Tsirka, S. E.,
Rogove, A. D.,
and Strickland, S.
(1996)
Nature
384,
123-124[Medline]
[Order article via Infotrieve]
9.
Akassoglou, K.,
Kombrinck, K. W.,
Degen, J. L.,
and Strickland, S.
(2000)
J. Cell Biol.
149,
1157-1166 10.
Hastings, G. A.,
Coleman, T. A.,
Haudenshild, C. C.,
Stefansson, S.,
Smith, E. P.,
Barthlow, R.,
Cherry, S.,
Sandkvist, M.,
and Lawrence, D. A.
(1997)
J. Biol. Chem.
272,
33062-33067 11.
Osterwalder, T.,
Cinelli, P.,
Baicia, A.,
Pennella, A.,
Krueger, S. R.,
Schrimpf, S. P.,
Meins, M.,
and Sonderegger, P.
(1998)
J. Biol. Chem.
273,
2312-2321 12.
Krueger, S. R.,
Ghisu, G. P.,
Cinelli, P.,
Gschwend, T., P.,
Osterwalder, T.,
Wolfer, D., P.,
and Sonderegger, P.
(1997)
J. Neurosci.
17,
8984-8996 13.
Yepes, M.,
Sandkvist, M.,
Wong, M. K.,
Coleman, T. A.,
Smith, E.,
Cohan, S. L.,
and Lawrence, D. A.
(2000)
Blood
96,
569-576 14.
Cinelli, P.,
Madani, R.,
Tsuzuki, N.,
Vallet, P.,
Arras, M.,
Zhao, C. N.,
Osterwalder, T.,
Rulicke, T.,
and Sonderegger, P.
(2001)
Mol. Cell. Neurosci.
18,
443-457[CrossRef][Medline]
[Order article via Infotrieve]
15.
Ye, S.,
Ceah, A. L.,
Belmares, R.,
Bergstom, R. C.,
Tong, Y.,
Corey, D. R.,
Kanost, M. R.,
and Goldsmith, E. J.
(2001)
Nat. Struct. Biol.
8,
979-983[CrossRef][Medline]
[Order article via Infotrieve]
16.
Lawrence, D. A.,
Ginsburg, D.,
Day, D. E.,
Berkenpas, M. B.,
Verhamme, I. M.,
Kvassman, J. O.,
and Shore, J. D.
(1995)
J. Biol. Chem.
270,
25309-25312 17.
Higazi, A. A.,
Upson, R. H.,
Cohen, R. L.,
Manuppello, J.,
Bognacki, J.,
Henkin, J.,
McCrae, K. R.,
Kounnas, M. Z.,
Strickland, D. K.,
Preissner, K. T.,
Lawler, J.,
and Cines, D. B.
(1996)
Blood
88,
542-551 18.
Potempa, J.,
Korzus, E.,
and Travis, J.
(1994)
J. Biol. Chem.
269,
15957-15960 19.
Huntington, J., A.,
Read, R. J.,
and Carrell, R. W.
(2000)
Nature
407,
923-926[CrossRef][Medline]
[Order article via Infotrieve]
20.
Strickland, D. K.,
Kounnas, M. Z.,
and Argraves, W. S.
(1995)
FASEB J.
9,
890-898[Abstract]
21.
Lawrence, D.,
Strandberg, L.,
Grundstrom, T.,
and Ny, T.
(1989)
Eur. J. Biochem.
186,
523-533[Medline]
[Order article via Infotrieve]
22.
Deutsch, D. G.,
and Mertz, E. T.
(1970)
Science
170,
1095-1096 23.
Schwartz, B. S.,
and Espana, F.
(1999)
J. Biol. Chem.
274,
15278-15283 24.
Laemmli, U. K.
(1970)
Nature
277,
680-685
25.
Gallagher, S.,
Winston, S. E.,
Fuller, S. A.,
and Hurrell, J. G. R.
(1997)
Current Protocols in Molecular Biology
, Vol. 2
, pp. 10.8.1-10.8.21, John Wiley & Sons, Etobicoke, Ontario, Canada
26.
Mussoni, L.,
Lawrence, D.,
and Loskutoff, D. L.
(1984)
Thromb. Res.
34 (suppl.),
241-254[CrossRef][Medline]
[Order article via Infotrieve]
27.
Schagger, H.,
and Jagow, G.
(1988)
Anal. Biochem.
173,
201-205[CrossRef][Medline]
[Order article via Infotrieve]
28.
Zhou, A.,
Carrell, R. W.,
and Huntington, J. A.
(2001)
J. Biol. Chem.
276,
27541-27547 29.
Gaussem, P.,
Grailhe, P.,
and Angles-Cano, E.
(1993)
J. Biol. Chem.
268,
12150-12155 30.
Gils, A.,
and Declerck, P. J.
(1998)
Thromb. Haemostasis
80,
286-291[Medline]
[Order article via Infotrieve]
31.
Kjoller, L.,
Martensen, P. M.,
Sottrup-Jensen, L.,
Justesen, J.,
Rodenburg, K. W.,
and Andreasen, P. A.
(1996)
Eur. J. Biochem.
241,
38-46[Medline]
[Order article via Infotrieve]
32.
Chen, Z. L.,
and Strickland, S.
(1997)
Cell
91,
917-925[CrossRef][Medline]
[Order article via Infotrieve]
33.
Osterwalder, T.,
Contartese, J.,
Stoeckli, E. T.,
Kuhn, T. B.,
and Sonderegger, P.
(1996)
EMBO
15,
2944-2953[Medline]
[Order article via Infotrieve]
34.
Zhang, J.-C.,
Sakthivel, R.,
Kniss, D.,
Grahm, C. H.,
Strickland, D. K.,
and McCrae, K. R.
(1998)
J. Biol. Chem.
273,
32273-32280 35.
Plotnick, M. I.,
Sandkur, M.,
Wang, Z. M.,
Liu, X.,
Rubin, H.,
Schechter, N. M.,
and Selwood, T.
(2002)
Biochemistry
41,
334-342[CrossRef][Medline]
[Order article via Infotrieve]
36.
Takao, M.,
Benson, M.,
Murrell, J.,
Yazaki, M.,
Piccardo, P.,
Unverzagt, F.,
Davis, R.,
Holohon, P.,
Laurence, D.,
Richardson, R.,
Fralow, M.,
and Ghetti, B.
(2000)
J. Neuropathol. Exp. Neurol.
59,
1070-1086[Medline]
[Order article via Infotrieve]
37.
Yepes, M.,
Sandkust, M.,
Coleman, T. A.,
Moore, E., Wu, J. Y.,
Mitola, D.,
Bugge, T. H.,
and Lawrence, D. A.
(2002)
J. Clin. Invest.
109,
1571-1578[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
S.-H. Li, N. V. Gorlatova, D. A. Lawrence, and B. S. Schwartz Structural Differences between Active Forms of Plasminogen Activator Inhibitor Type 1 Revealed by Conformationally Sensitive Ligands J. Biol. Chem., June 27, 2008; 283(26): 18147 - 18157. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Miranda, I. MacLeod, M. J. Davies, J. Perez, K. Romisch, D. C. Crowther, and D. A. Lomas The intracellular accumulation of polymeric neuroserpin explains the severity of the dementia FENIB Hum. Mol. Genet., June 1, 2008; 17(11): 1527 - 1539. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Bruno and A. C. Cuello Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade PNAS, April 25, 2006; 103(17): 6735 - 6740. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Onda, D. Belorgey, L. K. Sharp, and D. A. Lomas Latent S49P Neuroserpin Forms Polymers in the Dementia Familial Encephalopathy with Neuroserpin Inclusion Bodies J. Biol. Chem., April 8, 2005; 280(14): 13735 - 13741. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Miranda, K. Romisch, and D. A. Lomas Mutants of Neuroserpin That Cause Dementia Accumulate as Polymers within the Endoplasmic Reticulum J. Biol. Chem., July 2, 2004; 279(27): 28283 - 28291. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Makarova, I. Mikhailenko, T. H. Bugge, K. List, D. A. Lawrence, and D. K. Strickland The Low Density Lipoprotein Receptor-related Protein Modulates Protease Activity in the Brain by Mediating the Cellular Internalization of Both Neuroserpin and Neuroserpin-Tissue-type Plasminogen Activator Complexes J. Biol. Chem., December 12, 2003; 278(50): 50250 - 50258. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Molinari, V. Meskanaite, A. Munnich, P. Sonderegger, and L. Colleaux Extracellular proteases and their inhibitors ingenetic diseases of the central nervous system Hum. Mol. Genet., October 15, 2003; 12(90002): R195 - 200. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals |